NEW YORK — (AP) — Wall Street held near its record heights on Monday, ahead of a week likely to be dominated by updates from ...

A major U.S. drug manufacturing plant did not properly investigate cat hair, pests, and other problems, the FDA found in a ...

This week on "The Readout LOUD," we discuss Viking Therapeutics' obesity flop and dish on the growing "pharm to table" movement.

The most profitable trades in history often begin in moments of panic. And few moments felt more hopeless than the fall of ...

Pedersen and Maggie Fick COPENHAGEN (Reuters) -As Novo Nordisk's sales of its blockbuster weight-loss drug Wegovy boomed, the ...

As Novo Nordisk's sales of its blockbuster weight-loss drug Wegovy boomed, the Danish drugmaker raced to expand manufacturing capacity and sales outreach with a hiring spree that almost doubled staff ...

No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.

A report on August 20, 2025 shows that Representative Marjorie Taylor Greene from Georgia purchase stock in Novo Nordisk NVO +10.2% Get Free Report , valued between $15,001 and $50,000. According to ...

In the past year or couple of years, you’ve likely heard a lot about Ozempic, most likely in the context of weight loss. Not ...

Ascendis Pharma's TransCon platform shows promise, but challenges with rollout, competition, and execution risks lead to a ...

On Friday, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) had approved Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Wegovy has become a ...